This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Varian Strong on Global Expansion and Proton Therapy Arm
by Zacks Equity Research
Varian's (VAR) strong presence in China instills optimism in the stock.
Stryker (SYK) Q4 Earnings Beat, International Revenues Surge
by Zacks Equity Research
Stryker (SYK) gains from solid segmental contributions in Q4.
Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q1
by Zacks Equity Research
Hill-Rom (HRC) benefits from a solid year-over-year revenue increase on domestic growth in Q1, driven by strong segmental performance.
Intuitive Surgical (ISRG) Earnings Miss, Revenues Beat in Q4
by Zacks Equity Research
Solid show by flagship da Vinci system drives Intuitive Surgical's (ISRG) Q4 results.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
Here's Why Investors Should Hold AngioDynamics (ANGO) Now
by Zacks Equity Research
AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.
AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife
by Zacks Equity Research
AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.
AngioDynamics (ANGO) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 4.76% and 2.93%, respectively, for the quarter ended November 2018. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Hold AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics' (ANGO) gains from solid prospects in the NanoKnife platform. However, sluggishness in the Venous Insufficiency business is a headwind.
AngioDynamics (ANGO) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up
by Zacks Equity Research
AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.
AngioDynamics (ANGO) Lags Q1 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -11.11% and 2.36%, respectively, for the quarter ended August 2018. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Q1 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for AngioDynamics (ANGO) in Q1 Earnings?
by Zacks Equity Research
Expanding product portfolio, international market expansion and cost-saving initiatives to drive AngioDynamics (ANGO) in Q1.
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
New Strong Sell Stocks for September 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Why Is AngioDynamics (ANGO) Up 5.02% Since Its Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
Bear of the Day: AngioDynamics (ANGO)
by Kevin Cook
Small cap force in non-surgical alternatives for peripheral vascular disease hits a growth/valuation peak